Provectus Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Provectus Pharmaceuticals Inc Announces PV-10 Data On Locoregional Disease Control In Metastatic Melanoma
Provectus Pharmaceuticals Inc announced that an exploratory analysis of data on locoregional disease control in metastatic melanoma from completed Phase 2 study of intralesional PV-10 has been accepted for presentation at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), which will take place September 27 through October 1, 2013 in Amsterdam, The Netherlands. Provectus's PV-10, a 10% solution of Rose Bengal that is currently being examined as a cancer therapeutic, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, and significantly reduce the potential for systemic side effects. The Phase 2 study of melanoma patients looked at the effect of intralesional (IL) injection of PV-10 on selective ablation of injected lesions and for tumor-specific, immune-mediated bystander response in untreated lesions in which T cells are implicated.
Latest Developments for Provectus Pharmaceuticals Inc
Latest Key Developments in Biotechnology
- Recro Pharma, Inc announces pricing of its initial public offering
- GTx Inc closes private placement
- Prothena Corporation PLC gives FY 2014 net income guidance above analysts' estimates
- Neptune Technologies & Bioressources Inc announces closing of the over-allotment option associated with its recently completed public offering of common shares
- Share this
- Digg this